评价静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症有效性和安全性的临床研究
[Translation] Clinical study to evaluate the efficacy and safety of intravenous human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia
以原生产工艺静注人免疫球蛋白(pH4)对照,评价静注人免疫球蛋白(pH4)治疗原发免疫性血小板减少症的有效性和安全性。
[Translation] The efficacy and safety of intravenous injection of human immunoglobulin (pH4) in the treatment of primary immune thrombocytopenia were evaluated by the control of the original production process.
100 Clinical Results associated with Green Cross China Biological Products Co., Ltd.
0 Patents (Medical) associated with Green Cross China Biological Products Co., Ltd.
100 Deals associated with Green Cross China Biological Products Co., Ltd.
100 Translational Medicine associated with Green Cross China Biological Products Co., Ltd.